Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$38 Mln
P/E Ratio
--
P/B Ratio
7.64
Industry P/E
--
Debt to Equity
0
ROE
-1.73 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-4.28
CFO
$-207.76 Mln
EBITDA
$-302.35 Mln
Net Profit
$-292.40 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lumos Pharma (LUMO)
| 36.48 | -0.46 | 16.35 | 51.75 | -17.65 | -21.38 | -34.98 |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Lumos Pharma (LUMO)
| -11.91 | -47.91 | -80.59 | 56.83 | 66.45 | -81.09 | -21.11 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.98 | 2,341.96 | -- | -25.93 | |
| 13.26 | 21.14 | -- | -83.45 |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral... growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private. Read more
Founder, CEO & Chairman
Mr. Richard J. Hawkins
Founder, CEO & Chairman
Mr. Richard J. Hawkins
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lumos Pharma Inc (LUMO) stood at $ 24 Mln as on 30-Sep-24
The share price of Lumos Pharma Inc (LUMO) is $4.34 (NASDAQ) as of 13-Dec-2024 09:30 EDT. Lumos Pharma Inc (LUMO) has given a return of -17.65% in the last 3 years.
Lumos Pharma Inc (LUMO) has a market capitalisation of $ 38 Mln as on 13-Dec-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Lumos Pharma Inc (LUMO) is 7.64 times as on 13-Dec-2024, a 232% premium to its peers’ median range of 2.30 times.
Since, TTM earnings of Lumos Pharma Inc (LUMO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lumos Pharma Inc (LUMO) and enter the required number of quantities and click on buy to purchase the shares of Lumos Pharma Inc (LUMO).
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private.
The CEO & director of Mr. Richard J. Hawkins. is Lumos Pharma Inc (LUMO), and CFO & Sr. VP is Mr. Richard J. Hawkins.
There is no promoter pledging in Lumos Pharma Inc (LUMO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
234
|
|
|
2
|
|
|
234
|
|
|
2
|
| Lumos Pharma Inc. (LUMO) | Ratios |
|---|---|
|
Return on equity(%)
|
-312.41
|
|
Operating margin(%)
|
-1302.26
|
|
Net Margin(%)
|
-1583.49
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lumos Pharma Inc (LUMO) was $0 Mln.
